| Naing, Aung |
NCT06567314: Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 24 | US | Ivonescimab | M.D. Anderson Cancer Center, Summit Therapeutics | Cutaneous Squamous Cell Carcinoma | 09/28 | 09/30 | | |
NCT06651593: Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors |
|
|
| Not yet recruiting | 2 | 40 | US | SAR444881, Cemiplimab | M.D. Anderson Cancer Center, Regeneron Pharmaceuticals, Sanofi | Solid Tumors | 09/28 | 09/30 | | |
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies |
|
|
| Recruiting | 1/2 | 365 | US | GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475 | GV20 Therapeutics, Merck Sharp & Dohme LLC | Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer | 12/26 | 09/27 | | |
NCT05672459: A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors |
|
|
| Recruiting | 1/2 | 117 | US | Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide, leukapheresis | M.D. Anderson Cancer Center, Invectys | Solid Tumor | 06/26 | 12/29 | | |
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 285 | Europe, US, RoW | SAR445877, Cetuximab, Erbitux | Sanofi, Sanofi Aventis Recherche & Développement | Solid Tumor | 01/27 | 09/28 | | |
NCT04306224: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas |
|
|
| Completed | 1 | 12 | US, RoW | IMC-002 | ImmuneOncia Therapeutics Inc. | Solid Tumor, Lymphoma | 10/22 | 10/22 | | |
NCT04859777: A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors |
|
|
| Recruiting | 1 | 70 | US | MPT-0118, MPT-0118 + pembrolizumab | Monopteros Therapeutics Inc. | Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer | 03/23 | 03/23 | | |
AURELIO-03, NCT04234113: Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors |
|
|
| Terminated | 1 | 115 | Europe, US, RoW | Nanrilkefusp alfa, SOT101, SO-C101, RLI-15, Pembrolizumab, KEYTRUDA® | SOTIO Biotech AG, SOTIO Biotech a.s. | Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer | 08/24 | 11/24 | | |
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 91 | US | IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy | Immune-Onc Therapeutics, Regeneron Pharmaceuticals | Solid Tumor, Adult | 04/24 | 05/24 | | |
| Recruiting | 1 | 144 | US | NPX887 | NextPoint Therapeutics, Inc. | Metastatic Malignant Neoplasm | 08/27 | 08/27 | | |
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors |
|
|
| Completed | 1 | 22 | US | IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy | Immune-Onc Therapeutics | Solid Tumor, Adult | 03/24 | 05/24 | | |
| Recruiting | 1 | 260 | US, RoW | CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi® | Coherus Biosciences, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 12/25 | 08/26 | | |
| Recruiting | 1 | 40 | Europe, US, RoW | SOT201 | SOTIO Biotech AG | Advanced Solid Tumor, Metastatic Solid Tumor | 10/26 | 10/26 | | |
| Recruiting | 1 | 36 | US | ORB-021 | Orionis Biosciences Inc | Advanced Solid Tumors Cancer | 12/26 | 02/27 | | |
| Active, not recruiting | 1 | 198 | Europe, US | NG-350A plus Pembrolizumab, KEYTRUDA® | Akamis Bio, Merck Sharp & Dohme LLC | Epithelial Tumor, Metastatic Cancer | 03/25 | 05/25 | | |
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 |
|
|
| Recruiting | 1 | 131 | US | NPX267 | NextPoint Therapeutics, Inc. | Metastatic Malignant Neoplasm | 01/26 | 01/26 | | |
NCT06046066: A Phase 1 Study of NM6603 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 36 | US | NM6603 | NucMito Pharmaceuticals Co. Ltd. | Cancers | 02/26 | 07/26 | | |
| Nguyen, Andrew |
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) |
|
|
| Active, not recruiting | 3 | 354 | Europe, Canada, US, RoW | Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg | Novartis Pharmaceuticals | Giant Cell Arteritis (GCA) | 04/25 | 07/27 | | |
| Ulge, Umut |
| No trials found |
| Liu, Qian |
| No trials found |
